Source: The Hill Opinion

Summary

A recent opinion piece argues that the FDA’s data on mifepristone cannot be trusted due to its lack of robust, real-world sources. The article emphasizes the need for the FDA to prioritize credible data to ensure the integrity of its findings.

Why It Matters

Trust in FDA data is critical for public health and regulatory decisions, especially concerning medications like mifepristone. Inaccurate or incomplete data could lead to policy missteps affecting access and safety, amplifying public concern and eroding trust in healthcare agencies.

Read the full article →